arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Compass Therapeutics, Inc.

CMPX Health Care Biotechnology: Biological Products (No Diagnostic Substances)
$0.76
▼ -6.6% Today
as of Oct 23, 16:01 ET
Last 30 days -61.17% Sep 14 → Oct 23
$0.67 $1.01 $1.36 $1.71 $2.06 Sep 14 Sep 22 Sep 30 Oct 07 Oct 15 Oct 23
Open
$0.81
High
$0.84
Low
$0.78
Volume
$2M
Avg Vol
$4M
Mkt Cap
$184M
P/E (TTM)
—
Beta
—
52w High
$6.88
52w Low
$0.78
Div Yield
—
Shares Out
$180M

Recent Press Releases & News last 60 days · 10 items

Oct 14 · 20:30 PR GlobeNewswire
Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 14 · 02:13 Simply Wall St.
Compass Therapeutics (CMPX) Stock Fair Value Falls After Tovecimig Regulatory Concerns
Sep 23 · 18:18 MT Newswires
Compass Therapeutics Shares Drop After Downgrade From Wedbush
▸ Show all 10 press releases & news Free account →

CMPX earnings at a glance

Compass Therapeutics, Inc. (CMPX) is scheduled to report earnings on Wednesday, November 4, 2026 — in 12 days. Analysts expect earnings per share of -$0.12, compared with -$0.08 in the same quarter last year (-50%). The options market is pricing a move of about ±20.3% after the report, a range of roughly $0.61 to $0.91 from today's $0.76. Over its last 6 reports the stock rose the next day 5 times and fell 1, moving ±5.7% on average; after the most recent report on Aug 10, 2026 it moved +5.3%. That means options currently expect more movement than CMPX has typically delivered. CMPX beat the consensus EPS estimate in 2 of its last 6 reported quarters. Implied volatility is currently 172%. The share price of $0.76 sits near its 52-week low.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$0.78
$6.88
0% of range
Avg surprise (last 6)
+2.5%
Avg reaction (last 6)
+4.8%
83% positive
Latest IV / EM
172%
EM ±20.3% · $1 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.64$-0.38$-0.11$0.16$0.42 Actual $-0.12Est $-0.12Actual $-0.14Est $-0.13Actual $-0.08Est $-0.14Actual $-0.09Est $-0.10Actual $-0.10Est $-0.10Actual $-0.13Est $-0.10 Mar/2025Jun/2025Sep/20258KMar/2026Jun/2026
Revenue vs Net Income Revenue Net income
$-25M$-22M$-18M$-15M$-11M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Mon Aug 10, 2026Jun/2026 $-0.13 $-0.10 -30.0% +28.6% +5.3% earnings
Tue May 5, 2026Mar/2026 $-0.10 $-0.10 0.0% +16.7% +0.5% earnings
Thu Mar 5, 20268K 2026-03-05 $-0.09 $-0.10 +10.0% — -2.8% earnings
Wed Nov 5, 2025Sep/2025 $-0.08 $-0.14 +42.9% — +0.8% earnings
Mon Aug 11, 2025Jun/2025 $-0.14 $-0.13 -7.7% — +23.7% earnings
Thu May 8, 2025Mar/2025 $-0.12 $-0.12 0.0% — +1.1% earnings

Upcoming

DateFiscalTimeEPS EstLY EPSYoY %Δ
Wed Nov 4, 2026Sep/2026OTHER -$0.12-$0.08 -50.0%

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue———$0$0——$0
Cost of revenue————————
Gross profit————————
Operating income$-27M$-20M—$-16M$-21M$-18M—$-12M
Net income$-25M$-18M—$-14M$-20M$-17M—$-10M
EPS (diluted)————————

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$35M$55M$31M$46M$23M$41M$43M$19M
Inventory————————
Total current assets$181M$196M$210M$221M$106M$124M$133M$141M
Total assets$190M$205M$220M$231M$117M$131M$140M$149M
Long-term debt————————
Total liabilities$24M$19M$23M$22M$23M$21M$15M$11M
Total equity$166M$186M$197M$210M$93M$110M$125M$138M

Implied volatility — last 90 days

72%219%365%512%659% Jun 07 — IV 88% · EM ±12.3%Jun 08 — IV 94% · EM ±12.4%Jun 09 — IV 97% · EM ±12.1%Jun 10 — IV 88% · EM ±10.4%Jun 11 — IV 101% · EM ±11.2%Jun 12 — IV 72% · EM ±7.4%Jun 15 — IV 101% · EM ±7.3%Jun 16 — IV 128% · EM ±7.6%Jun 19 — IV 112% · EM ±24.8%Jun 22 — IV 97% · EM ±20.3%Jun 23 — IV 83% · EM ±16.9%Jun 24 — IV 99% · EM ±19.8%Jun 25 — IV 80% · EM ±15.7%Jun 26 — IV 88% · EM ±16.8%Jun 29 — IV 105% · EM ±18.5%Jun 30 — IV 93% · EM ±16.0%Jul 01 — IV 82% · EM ±13.8%Jul 02 — IV 103% · EM ±16.7%Jul 03 — IV 106% · EM ±16.5%Jul 06 — IV 118% · EM ±16.4%Jul 07 — IV 212% · EM ±28.0%Jul 08 — IV 242% · EM ±30.3%Jul 09 — IV 220% · EM ±26.0%Jul 10 — IV 253% · EM ±27.9%Jul 13 — IV 318% · EM ±26.5%Jul 14 — IV 283% · EM ±20.5%Jul 15 — IV 237% · EM ±14.0%Jul 16 — IV 399% · EM ±16.7%Jul 20 — IV 100% · EM ±23.5%Jul 21 — IV 102% · EM ±23.6%Jul 22 — IV 91% · EM ±20.8%Jul 23 — IV 84% · EM ±18.9%Jul 24 — IV 87% · EM ±19.3%Jul 27 — IV 127% · EM ±26.4%Jul 28 — IV 84% · EM ±17.2%Jul 29 — IV 90% · EM ±18.1%Jul 30 — IV 105% · EM ±20.6%Jul 31 — IV 123% · EM ±23.6%Aug 03 — IV 97% · EM ±17.2%Aug 04 — IV 110% · EM ±18.9%Aug 05 — IV 111% · EM ±18.5%Aug 06 — IV 101% · EM ±16.4%Aug 07 — IV 156% · EM ±24.4%Aug 10 — IV 114% · EM ±15.8%Aug 11 — IV 129% · EM ±17.0%Aug 12 — IV 185% · EM ±23.2%Aug 13 — IV 206% · EM ±24.3%Aug 14 — IV 302% · EM ±33.3%Aug 17 — IV 283% · EM ±23.6%Aug 18 — IV 407% · EM ±29.4%Aug 19 — IV 614% · EM ±36.3%Aug 20 — IV 659% · EM ±27.5%Aug 24 — IV 246% · EM ±51.4%Aug 25 — IV 135% · EM ±27.7%Aug 26 — IV 216% · EM ±43.2%Aug 27 — IV 157% · EM ±30.8%Aug 28 — IV 207% · EM ±39.6%Aug 31 — IV 249% · EM ±44.1%Sep 01 — IV 239% · EM ±41.1%Sep 02 — IV 197% · EM ±32.9%Sep 03 — IV 235% · EM ±38.0%Sep 04 — IV 229% · EM ±35.7%Sep 07 — IV 258% · EM ±35.7%Sep 08 — IV 171% · EM ±22.6%Sep 09 — IV 275% · EM ±34.4%Sep 10 — IV 165% · EM ±19.5%Sep 11 — IV 223% · EM ±24.6%Sep 14 — IV 226% · EM ±18.8%Sep 15 — IV 237% · EM ±17.1%Sep 16 — IV 391% · EM ±23.1%Sep 17 — IV 582% · EM ±24.3%Sep 21 — IV 171% · EM ±35.7%Sep 22 — IV 293% · EM ±60.0%Sep 23 — IV 233% · EM ±46.6%Sep 30 — IV 115% · EM ±19.2%Oct 01 — IV 202% · EM ±32.6%Oct 02 — IV 180% · EM ±28.1%Oct 06 — IV 152% · EM ±20.0%Oct 07 — IV 156% · EM ±19.6%Oct 08 — IV 172% · EM ±20.3%

Sector peers

CRDL
Cardiol Therapeutics Inc.
$189M $1.12-4.3%
DTIL
Precision BioSciences, Inc.
$173M $6.64-1.0%
VYGR
Voyager Therapeutics, Inc.
$165M $1.74-13.9%
OTLK
Outlook Therapeutics, Inc.
$165M $0.52-7.4%
TARA
Protara Therapeutics, Inc.
$163M $2.33-6.8%
IPHA
Innate Pharma S.A.
$208M $1.48-5.7%

CMPX earnings FAQ

When is CMPX's next earnings date?

Compass Therapeutics, Inc. is expected to report on November 4, 2026.

What is CMPX's expected move for earnings?

Options currently price a move of about ±20.3%, or $0.15 per share either way from $0.76.

How does CMPX stock usually react to earnings?

Across the last 6 reports the average next-day move was ±5.7%, up 5 times and down 1 times.

What EPS are analysts expecting from Compass Therapeutics, Inc.?

The consensus estimate is -$0.12 per share, versus -$0.08 a year ago.

What is CMPX's implied volatility?

CMPX's at-the-money implied volatility is about 172% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in